Table 2.
CETP, LCAT, LPL, OxPL, apolipoproteins and nuclear magnetic resonance spectroscopy-measured lipid levels and size of participants of the EPIC-Norfolk study classified on the basis of PCSK9 R46L carrier status.
| Non-carriers | N | Carriers | N | D (%) | D (SD) | P*2 | |
|---|---|---|---|---|---|---|---|
| CETP, mg/L | 2.9(2.2-3.8) | 2099 | 2.9(1.9-4.0) | 71 | 0.3% | 0.00 | 1.00 |
| LCAT, µg/ml | 8.9(±2.2) | 2071 | 8.7(±2.3) | 68 | -2.2% | -0.09 | 0.47 |
| LPL, ng/ml | 62.5(44.1-88.8) | 2239 | 61.4(51.8-81.2) | 76 | -1.7% | 0.04 | 0.95 |
| OxPL, RLU | 1694.0(1167.0-2670.0) | 1997 | 1573.5(1093.0-3128.0) | 66 | -7.1% | -0.04 | 0.83 |
| CRP, mg/L | 1.7 (0.8-14.0) | 2296 | 1.9(0.8-14.2) | 77 | 11.8% | 0.03 | 0.72 |
| WBC, 10^3/µl | 6.7(±1.9) | 2852 | 6.9(±2.0) | 96 | 2.9% | 0.10 | 0.20 |
| sPLA2, nmol/ml/min* | 4.6(±1.3) | 2373 | 4.2(±0.9) | 77 | -8.7% | -0.33 | 0.0036 |
| Lp-PLA2, nmol/ml/min* | 52.4(±16,2) | 2373 | 47.5(±14.1) | 77 | -9.4% | -0.30 | 0.0154 |
| Apolipoprotein B, mg/dL* | 133.9(±32.5) | 2105 | 119.6(±31.9) | 75 | -10.7% | -0.44 | <0.001 |
| Apolipoprotein A-I, mg/dL | 158.6(±28.4) | 1971 | 160.2(±27.5) | 73 | 1.1% | 0.06 | 0.79 |
| Apolipoprotein A-II, mg/L | 35.2(±6.1) | 2280 | 34.5(±5.3) | 77 | -2.1% | -0.12 | 0.22 |
| Apolipoprotein A-V, ng/mL | 180.0(141.6-235.6) | 2236 | 193.7(159.2-266.5) | 76 | 7.6% | 0.17 | 0.15 |
| Lipoprotein(a), mg/dL* | 12.4(6.7-29.1) | 2296 | 11.1(7.2-28.6) | 77 | -10.3% | -0.04 | <0.001 |
| VLDL Size, nm | 51.8(±8.7) | 2296 | 52.6(±10.0) | 77 | 1.4% | 0.09 | 0.30 |
| LDL Size, nm | 21.0(±0.6) | 2296 | 21.0(±0.7) | 77 | 0.3% | 0.09 | 0.73 |
| HDL Size, nm | 8.9(±0.5) | 2296 | 9.0(±0.4) | 77 | 1.3% | 0.24 | 0.12 |
| VLDL-P (total), nmol/L* | 99.0(±33.3) | 2296 | 85.8(±26.2) | 77 | -13.3% | -0.40 | <0.001 |
| Large VLDL/Chylomicrons, nmol/L | 4.7(1.8-7.8) | 2296 | 3.6(1.7-6.9) | 77 | -22.1% | -0.21 | 0.11 |
| Medium VLDL, nmol/L* | 34.6(±17.7) | 2296 | 29.0(±14.6) | 77 | -16.4% | -0.32 | 0.0082 |
| Small VLDL, nmol/L* | 59.1(±18.7) | 2296 | 52.4(±18.7) | 77 | -11.2% | -0.35 | 0.0021 |
| NMR LDL-P, nmol/L* | 1662.9(±458.3) | 2296 | 1479.7(±396.8) | 77 | -11.0% | -0.40 | <0.001 |
| IDL, nmol/L* | 38.3(16.4-71.7)) | 2296 | 31.5(11.0-61.1) | 77 | -17.8% | -0.24 | 0.0393 |
| Large LDL, nmol/L* | 565.9(±206.4) | 2296 | 517.0(±192.1) | 77 | -8.7% | -0.24 | 0.0088 |
| Medium small LDL, nmol/L | 191.8(141.6-264.4) | 2296 | 164.7(124.9-230.5) | 77 | -14.1% | -0.22 | 0.12 |
| Very small LDL, nmol/L | 764.5(565.9-1044.6) | 2296 | 654.5(480.2-909.2) | 77 | -14.4% | -0.26 | 0.06 |
| NMR HDL-P, µmol/L | 33.8(±5.6) | 2296 | 34.3(±4.7) | 77 | 1.6% | 0.10 | 0.51 |
| Large HDL, µmol/L | 5.0(2.8-7.7) | 2296 | 6.1(3.9-8.3) | 77 | 23.2% | 0.24 | 0.11 |
| Medium HDL, µmol/L | 2.6(1.1-4.9) | 2296 | 3.4(1.4-5.0) | 77 | 29.5% | 0.05 | 0.64 |
| Small HDL, µmol/L | 24.9(±5.0) | 2296 | 24.4(±4.3) | 77 | -1.8% | -0.09 | 0.54 |
| LDL cholesterol, mmol/L |
Data are presented as mean ± standard deviation for variables with a normal distribution and median with interquartile range for variables with a non-normal distribution. N= number, D = difference, D (SD) = difference as proportion of standard deviation, NMR = nuclear magnetic resonance, CETP = cholesteryl ester transfer, LCAT = lecithin - cholesterol acyltransferase, LPL = lipoprotein lipase, OxPL = oxidized phospholipids, RLU = relative light units, CRP = C-reactive protein, secretory phospholipase A2= sPLA2, lipoprotein-associated phospholipase A2 = Lp-PLA2, WBC = white blood cells, VLDL = very low density lipoprotein, LDL = low-density lipoprotein, IDL = intermediate-density lipoprotein, HDL = high-density lipoprotein, SD = standard deviation.
significant difference.
P*2 values calculated with a linear regression model, adjusted for age, sex and CVD status.